Some of its rivals already have chalked up big pharma deals around in vivo antibody platforms, most notably Ablexis LLC, of San Francisco, which received backing from a consortium of five companies to develop its AlivaMab Mouse platform, including founding investor Pfizer Inc., of New York, all of which gained nonexclusive access to its technology

Inc., of Whitehouse Station, N.J., entered into a nonexclusive deal with Bristol-Myers Squibb Co., of New York, to conduct a Phase II trial of a once-daily oral combination regimen consisting of BMS' NS5A replication complex inhibitor daclatasvir and Merck's NS3/4A protease inhibitor MK-5172 to treat chronic hepatitis C virus infection genotype 1

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER Cevec Pharmaceuticals GmbH (Cologne, Germany) Yuhan Corp. (Seoul, South Korea) ND CAP-Technology licensing deal enabling Yuhan to use Cevec's CAP-T and CAP cell expression systems for the production and development of various therapeutic proteins Financial terms were not disclosed 12/21/12 GlaxoSmithKline plc (London) The University of Texas MD Anderson Cancer Center (Houston) $335 Research

AstraZeneca will pay milestones and royalties to CRT 3/7/13 KineMed Inc. (Emeryville, Calif.) Pfizer Inc. (New York) ND Renewed nonexclusive research collaboration to advance approaches for treating metabolic disease, in particular Type II diabetes The collaboration will use KineMed's dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways 3/28/13 Sagent Pharmaceuticals Inc. (Schaumburg, Ill.) Actavis Inc. (Parsippany, N.J

GlycoVaxyn received an up-front payment and equity investment from GSK and is eligible for milestone payments and royalties on licensed vaccine candidates 12/20/12 Halozyme Therapeutics Inc. (San Diego) Pfizer Inc. (New York) $515 Worldwide collaboration and license agreement to develop and commercialize products that combine recombinant human hyaluronidase enzyme (rHuPH20) with biologics directed to up to six unnamed targets Halozyme will receive an initial payment of $8M, which includes the up

The venture capital environment in biotech is severely stressed," said Jonathan Leff, partner at New York-based Deerfield Management and chairman of the Deerfield Institute, who serves on the boards for both BIO and the NVCA and has attended the convention for most of his 17 years as a venture capitalist

Previously, he was an associate professor at the Karolinska Institute in Stockholm, Sweden, after completing a postdoctoral research fellowship at Rockefeller University in New York

New York-based BMS will hold worldwide rights to whatever products emerge from the alliance...Its other partners include New York-based Pfizer Inc

GlycoMimetics partnered GMI-1070, a synthetic glycomimetic molecule designed to inhibit all three selectin types, in a worldwide agreement with Pfizer Inc., of New York, in 2011. (See BioWorld Today, Oct. 12, 2011

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported top-line results from a six-month pivotal Phase III study testing fixed-dose combinations of aclidinium bromide, a long-acting muscarinic beta2 agonist, and formoterol fumarate, a long-acting beta2 agonist, delivered using Almirall's inhaler Genuair

M&A strategies in our business are hit and miss," said Eric Schmidt, managing director and senior research analyst at Cowen & Co., in New York

New York-based BMS will hold worldwide rights to whatever products emerge from the alliance...Its other partners include New York-based Pfizer Inc

Merck KGgA, of Darmstadt, Germany, reported that a collaboration agreement between its subsidiary, EMD Serono Inc., and Pfizer Inc., of New York, inked in July 2002 for the co-promotion of multiple sclerosis drug Rebif (interferon beta-1a) extends until Dec. 31, 2015, according to an appellate court ruling

The three-way arrangement with Pfizer and BMS, both of New York, to test a candidate that could reverse the anticoagulant effects of Factor Xa inhibitors may help all three firms eventually, but Portola was paid first

The three-way arrangement with Pfizer and BMS, both of New York, to test a candidate that could reverse the anticoagulant effects of Factor Xa inhibitors may help all three firms eventually, but Portola was paid first

Merck KGgA, of Darmstadt, Germany, reported that a collaboration agreement between its subsidiary, EMD Serono Inc., and Pfizer Inc., of New York, inked in July 2002 for the co-promotion of multiple sclerosis drug Rebif (interferon beta-1a) extends until Dec. 31, 2015, according to an appellate court ruling

M&A strategies in our business are hit and miss," said Eric Schmidt, managing director and senior research analyst at Cowen & Co., in New York

Kythera Biopharmaceuticals Inc., of New York, reported that MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF), commonly known as double chin, during an oral session at the Aesthetic Meeting 2013 in New York

Bristol-Myers Squibb Co., of New York, named Francis Cuss executive vice president and chief scientific officer, effective July 1